Novo Nordisk: Growth hormone med phase 2 data demonstrates potential

Novo Nordisk announced that somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of once-daily Norditropin in a phase 2 trial in children with growth hormone deficiency. The REAL 3 trial data were presented today at the 57th Annual Meeting of the European Society for Paediatric Endocrinology. The trial compared three somapacitan doses to Norditropin 0.034 mg/kg/day. Annualized height velocity did not differ significantly for the 0.08 and 0.16 mg/kg/wk doses compared to Norditropin. The mean annualized height velocity for the three dose levels of somapacitan was 8.0 cm, 10.9 cm and 12.9 cm, respectively, as compared to 11.4 cm for daily Norditropin. Somapacitan was well tolerated at all doses investigated, with no clinically relevant safety or local tolerability issues identified.
https://thefly.com/landingPageNews.php?id=2796921